



**American Hospital  
Association®**

800 10th Street, NW  
Two CityCenter, Suite 400  
Washington, DC 20001-4956  
(202) 638-1100 Phone  
[www.aha.org](http://www.aha.org)

September 29, 2016

The Honorable Peter Welch  
U.S. House of Representatives  
2303 Rayburn House Office Building  
Washington, DC 20515

The Honorable Morgan Griffith  
U.S. House of Representatives  
1108 Longworth House Office Building  
Washington, DC 20515

Dear Representatives Welch and Griffith:

On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations – including 1,860 hospitals that participate in the 340B Drug Pricing Program – the American Hospital Association (AHA) writes to share our support for H.R. 6174, the Closing Loopholes for Orphan Drugs Act.

The current orphan drug exclusion policy prevents 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals from purchasing some medically necessary drugs at the 340B price. This bill would allow 340B hospitals subject to the orphan drug exclusion to purchase orphan drugs through the 340B program when the drugs are used to treat an illness other than the rare conditions for which the orphan drug designation was given. The AHA has long supported efforts to allow these 340B hospitals to access 340B pricing because it would help them provide patients in these rural communities access to more affordable drugs near where they live.

For nearly 25 years, the 340B program has provided financial relief from high prescription drug costs to certain health care providers that care for low-income and indigent populations. Hospitals use the 340B savings to provide clinical pharmacy services, financial assistance to patients unable to afford their prescriptions, oncology services and community outreach programs, among others. In an era of rapidly rising prescription drug costs, this bill is an important step to ensure that 340B hospitals subject to the orphan drug exclusion can obtain lifesaving drugs at a much needed discount so they can stretch limited resources to better serve their communities.

Thank you for leadership on this important issue. Please contact me if you have questions or feel free to have a member of your team contact Aimee Kuhlman, AHA senior associate director of federal relations, at [akuhlman@aha.org](mailto:akuhlman@aha.org) or (202) 626-2291.

Sincerely,

//s//

Thomas P. Nickels  
Executive Vice President

